case_id,mode,iteration,Q8_reasoning,has_no_in_pred
Case3223,rag,iter2,"Although the BRCA1/2 coverage criteria are contained in a separate review (2.04.02) not provided here, the supplied policy states genetic testing (including BRCA1/2 strategy referenced) should be made available to individuals without a personal history of breast cancer when they meet NCCN guideline criteria. The patient has a first-degree relative with epithelial ovarian cancer, which the policy cites as a family-history-based trigger for guideline-driven genetic risk evaluation; therefore, based on the provided policy language and the patient's family history, BRCA1/2 testing would be considered covered.",False
Case3422,rag,iter2,"Under CCA Clinical Coverage Criteria, all applicable conditions are met: member displays a relevant clinical feature/personal history (congenital choanal atresia) (1.a), prior testing (CMA) was nondiagnostic (1.b), exome sequencing is listed in the CPT table (81415), and the patient has had genetic counseling visits (supporting provider/counseling expertise). Prior authorization is required per the MNG. Therefore, based on the provided patient facts and the MNG, the test meets the policy coverage criteria.",False
Case3465,rag,iter2,"Per policy, standard WGS may be considered medically necessary for pediatrics <21 when criteria are met. The patient (age 2) was evaluated by a genetics expert, had counseling, prior genetic testing was nondiagnostic, family history supports genetic etiology, and relevant CPT code (81425) is listed as covered when medically necessary.",False
Case15202,rag,iter2,"Within the provided policy text, the American Society of Breast Surgeons guidance (included in the document) states BRCA1/2 testing should be available to individuals with a personal history of breast cancer. The benefit application portion states benefits are available for specialized diagnostic genetic testing when medically necessary. The patient has a personal history of malignant breast tumor and has completed pre-test counseling; therefore, based on the policy text and patient facts, BRCA1/2 testing would be covered.",True
Case14141,rag,iter2,"Based on policy I and patient facts: patient is pediatric (<21), has multiple congenital anomalies, prior CMA nondiagnostic (meets the 'previous testing non-diagnostic' criterion), pre-test genetic counseling completed, and CPT 81415 (WES) is listed as covered when medically necessary. These elements satisfy the policy coverage criteria for standard WES.",False
Case6747,rag,iter2,"Based on policy MP 2.324 the patient meets all required elements for standard WGS: age <21, evaluation by a genetics clinician, counseling provided, and prior CMA nondiagnostic with a suspected genetic etiology — therefore WGS is medically necessary and covered per the policy.",False
Case950,rag,iter2,"Under the policy, genetic testing for infantile-/early-childhood-onset epileptic encephalopathies is medically necessary when criteria are met (onset before age 5, severe encephalopathy/epilepsy as primary symptom, no other syndrome). The patient meets these criteria (onset <3 years, unexplained epileptic encephalopathy, karyotype nondiagnostic), and has had genetic counseling; therefore WES is covered per the policy's medically necessary statement.",False
Case9408,rag,iter2,"Under the policy, genetic testing may be considered medically necessary for infantile/early-childhood-onset epileptic encephalopathies when results may affect management. Patient has epileptic encephalopathy with onset <5 years, CMA nondiagnostic, testing ordered by a medical geneticist, and pre-test counseling — meeting the policy's clinical application for coverage.",False
Case12834,rag,iter2,"Per the guideline and cited professional recommendations within the document (ACMG/AAP/AACAP), chromosomal microarray is a recommended/first-tier test for individuals with unexplained neurodevelopmental disorders/ID/GDD. The patient is a 16-year-old with complex neurodevelopmental disorder and prior Fragile X testing nondiagnostic, meeting the coverage-related clinical indication for CMA.",True
Case19255,rag,iter2,"Under the policy, germline BRCA1/2 testing is medically necessary for individuals with a personal history of breast cancer meeting listed criteria (diagnosed ≤45 and/or multiple primaries). The patient is 38 with two primary breast cancers, has relevant family history, and completed genetic counseling, therefore coverage is supported by the policy.",False
Case2211,rag,iter2,"Per FEP 2.04.02 policy, testing is medically necessary for individuals with any close blood relative with a known BRCA pathogenic variant. The patient’s mother has a known BRCA2 pathogenic variant, the patient is an adult, and pre-test genetic counseling was completed—so coverage is supported by the policy statement.",False
Case14408,rag,iter2,"Per the policy, genetic testing for BRCA1/2 in an unaffected individual is medically necessary if they have a 1st- or 2nd-degree relative meeting Patients With Cancer criteria; the patient has a brother with breast cancer (male breast cancer meets the listed criterion), pre-test counseling was completed, and testing is therefore covered under the policy.",False
Case9978,rag,iter2,"Per the policy, genetic testing is considered medically necessary for infantile- or early-childhood-onset epileptic encephalopathies when epilepsy is the core symptom. The patient had seizure onset before age 5 and has epileptic encephalopathy; pre-test genetic counseling was completed, so the request meets the policy's medically necessary application.",False
Case5605,rag,iter2,Per policy II.2.a.i the patient is symptomatic with a suspected genetic disorder (congenital cardiac anomaly); pre-test genetic counseling was completed and prior CMA was nondiagnostic (supporting that other testing is equivocal). Taken together these facts meet the policy's indications for covered germline genomic testing.,False
Case16487,rag,iter2,"Per the policy, WES (or rapid WES) may be considered medically necessary for infants/children with high-risk BRUE when criteria are met. Patient is an infant with recurrent high-risk BRUE (policy-listed clinical feature), prior genetic testing was nondiagnostic (FISH), pre-test counseling was completed, and there is potential to change management—together supporting that WES is covered per the policy.",True
Case3677,rag,iter2,"Based on policy MOL.TS.238.A the patient meets age (≥18), medical indication (personal breast cancer ≤50 and family pancreatic cancer/multiple affected relatives), has required pre-test counseling, and has no prior BRCA sequencing reported — thus BRCA1/2 testing is covered per the guideline.",False
Case7682,rag,iter2,"All policy-required elements for medically necessary standard WES are met: child with multiple congenital anomalies, evaluated/counseled by genetics specialist, prior genetic testing nondiagnostic, relevant family history—thus WES may be considered medically necessary per the policy statement.",False
Case14127,rag,iter2,"All policy-required elements for standard WES are met (age <21, evaluated by genetics, counseling provided, prior testing nondiagnostic, relevant clinical/family history); per policy WES may be considered medically necessary.",False
Case15820,rag,iter2,"Per the policy, CMA 'may be considered medically necessary as first-line testing' for apparent nonsyndromic developmental delay/intellectual disability, which matches the patient's presentation; therefore coverage is supported.",False
Case19321,rag,iter2,"Per policy, WES may be medically necessary for children with unexplained neurodevelopmental disorders when: (1) evaluation by a genetics-expert with family history/phenotype description and counseling is documented, (2) there is potential to change management, and (3) prior testing (eg, CMA) failed to yield a diagnosis. Patient has an unexplained neurodevelopmental disorder, prior CMA was nondiagnostic (criterion 3), family history and phenotype documented, and pre-test genetic counseling completed (criterion 1). The clinical team is pursuing WES (implying potential to change management). Therefore, the facts provided satisfy the policy requirements for coverage.",True
Case6867,rag,iter2,"Within the provided policy text, the American Society of Breast Surgeons guidance (included in the document) states BRCA1/BRCA2 testing should be made available to individuals with a personal history of breast cancer. The patient has a personal history of breast cancer, appropriate genetic counseling, and relevant family history; based on these policy statements and Benefit Application language that medically necessary specialized diagnostic genetic testing is covered, BRCA1/2 testing is covered.",False
Case2007,rag,iter2,"From an adjudication perspective using only the provided policy text: the benefit section permits specialized diagnostic genetic testing when medically necessary, and the policy cites ASBS guidance that BRCA1/2 testing 'should be made available to all individuals with a personal history of breast cancer.' The patient has metastatic breast cancer and completed counseling, therefore BRCA1/2 testing would be considered covered per the policy guidance and benefit application.",False
Case7297,rag,iter2,"Based on policy, WES is medically necessary for a child with unexplained multiple congenital anomalies when (1) evaluated/counseled by genetics specialist, (2) prior genetic testing was nondiagnostic, and (3) results may change management. The patient meets these requirements; therefore WES is covered per the policy statement.",False
Case2666,rag,iter2,"Per policy, testing is medically necessary for an unaffected individual who has a 1st-degree relative meeting criteria for cancer-affected individuals; the patient's father has metastatic prostate cancer (meets A.6), the patient had appropriate pre-test genetic counseling, is an adult, and comprehensive BRCA1/2 testing (CPT 81162) is consistent with policy. (Policy A.6; Policy B.1; Policy Guidelines re: counseling and comprehensive testing)",False
Case15458,rag,iter2,Policy and cited guidelines in the document (American Society of Breast Surgeons and benefit application stating coverage for medically necessary specialized diagnostic genetic testing) support availability/coverage of BRCA1/2 testing for individuals with a personal history of breast cancer; patient meets that indication and completed pre-test counseling.,False
Case18868,rag,iter2,"Policy states genetic testing of the individual's genome MEETS COVERAGE once per lifetime when criteria are met (symptomatic patient where results can impact management) (II.2). The patient is symptomatic with cancer, meets clinical indication, age, and ordering by a specialist, so WGS is covered under the policy.",False
Case10917,rag,iter2,"Per the policy, standard WES may be medically necessary for evaluation of unexplained congenital disorders when (1) evaluated and counseled by a genetics clinician (met), (2) there is potential to change management (reasonable given workup for unexplained conjugated hyperbilirubinemia), and (3) a genetic etiology is considered likely (policy explicitly lists conjugated hyperbilirubinemia as an abnormal lab suggesting genetic disease and patient has relevant family history). Documentation in the record satisfies policy criteria except for unspecified details about prior testing (see Q4), and on balance the clinical presentation aligns with policy examples permitting coverage.",False
Case16246,rag,iter2,"On adjudication of coverage criteria in the policy, the patient meets medical-necessity criteria for BRCA1/2 testing (personal history of breast cancer diagnosed ≤45 years and relevant family history). The policy also requires testing be done in a setting that can provide pre/post-test counseling; lack of documented pre-test counseling should be addressed operationally but does not negate that the patient meets coverage criteria.",True
Case9773,rag,iter2,"Under the policy, germline/genomic testing meets coverage when the patient is symptomatic and testing will assist diagnosis/management. The child has severe intellectual disability with suspected genetic etiology, no conflicting policy exclusions apply, and required pre-test genetic counseling was completed, supporting coverage.",False
Case3223,rag,iter3,"Although the full BRCA coverage policy (2.04.02) is not included, the provided policy references that BRCA1/2 testing strategy is described in that related policy and states genetic testing should be available to individuals without a personal history of breast cancer when they meet NCCN guideline criteria. Given the patient has a first-degree relative with epithelial ovarian cancer (a family history highlighted by the policy as relevant), and the Benefit Application states medically necessary specialized diagnostic genetic testing is a covered benefit, BRCA1/2 testing is covered when guideline criteria are met — which, based on the policy text and the patient’s family history, supports coverage.",False
Case15202,rag,iter3,"Based on the policy citations (American Society of Breast Surgeons guidance noted in the document) that genetic testing should be made available to individuals with a personal history of breast cancer, and given the patient has a personal history of a malignant breast tumor and has completed pre-test genetic counseling, BRCA1/2 testing would be considered covered as medically necessary per the policy's cited guidance and the Benefit Application clause that genetic testing is covered when medically necessary.",True
Case8621,rag,iter3,"Under the policy, standard WES may be medically necessary for children with unexplained neurodevelopmental disorders when ALL criteria are met. The patient: is a child with an unexplained neurodevelopmental disorder (meets indication), had prior CMA nondiagnostic (meets prior-testing criterion), and has completed pre-test genetic counseling. Although the ordering provider is an oncologist (Q2), documentation shows evaluation/counseling by a genetic counselor meeting the policy's counseling/expertise requirement. The family seeks a unifying diagnosis (implying potential to change management). Therefore the case meets the policy's criteria for coverage.",True
Case950,rag,iter3,"Per the policy the patient has unexplained early-onset epileptic encephalopathy (onset <3 years), no known underlying cause, and has not had prior epilepsy panel testing — criteria supported by the guideline for genetic NGS-based testing (and the guideline references ES/GS as appropriate). Therefore WES is covered.",True
Case9408,rag,iter3,"Under the FEP policy, genetic testing is considered medically necessary for infantile/early-childhood-onset epileptic encephalopathies. The patient has early-onset epileptic encephalopathy (onset <5 years), prior nondiagnostic CMA, and pre-test counseling — meeting the policy indication for medically necessary testing.",False
Case12834,rag,iter3,"Under the policy, CMA may be considered medically necessary as first-line testing for individuals with developmental delay/intellectual disability/ASD; the patient meets that clinical indication (16-year-old with complex neurodevelopmental disorder and prior nondiagnostic fragile X).",False
Case19255,rag,iter3,"Patient meets policy criteria for BRCA full sequence testing: age ≥18, documented pre-test genetic counseling, no prior BRCA full sequencing, medical indication of two separate primary breast cancers, and relevant family history (father with metastatic prostate cancer). Therefore testing is covered per the BRCA Analysis criteria.",True
Case2211,rag,iter3,"Per the policy, genetic testing for BRCA1/2 is medically necessary for individuals with any close blood relative with a known pathogenic BRCA variant. The patient is an adult, has a mother with a known BRCA2 pathogenic variant, has appropriate pre-test genetic counseling, and therefore meets coverage criteria.",False
Case9978,rag,iter3,"Under FEP 2.04.109, genetic testing for genes associated with infantile- and early-childhood-onset epileptic encephalopathies may be considered medically necessary when criteria are met (onset <5 years, severe epilepsy/encephalopathy, no better explanatory syndrome). Patient had seizure onset before age 3 with an epileptic encephalopathy diagnosis, and thus meets the policy's medically necessary indication for genetic testing (basis: Policy Statement and Policy Guidelines).",False
Case5605,rag,iter3,"Based on policy, standard WGS is medically necessary for pediatric patients <21 with unexplained congenital anomalies when evaluated by a genetics expert, prior genetic testing is nondiagnostic, and there is potential to change management. Patient is 11, had nondiagnostic CMA, received genetics counseling, and meets the policy criteria; therefore WGS is covered.",True
Case15834,rag,iter3,"Per policy, standard WES may be considered medically necessary for children with unexplained neurodevelopmental disorders when all criteria are met. Patient facts document: evaluation/counseling by a genetic specialist, prior targeted testing (Fragile X) nondiagnostic, a neurodevelopmental concern (early ASD signs), and relevant family history—together satisfy the policy's stated criteria for coverage.",False
Case16487,rag,iter3,"Per policy, WES may be medically necessary when all criteria are met: (1) evaluation/counseling by genetics (documentation required) — patient has pre-test counseling and planned post-test genetic follow-up; (2) potential for change in management — high-risk BRUE diagnosis can affect management; and (3) prior genetic testing failed to yield a diagnosis — nondiagnostic FISH. The phenotype (high-risk BRUE with recurrent events without respiratory infection) is specifically listed in policy examples. Based on these facts and the policy criteria, the test is covered.",False
Case3677,rag,iter3,"Per the policy (AHS–M2003), BRCA1/2 testing meets coverage for an individual with breast cancer who has a close blood relative with pancreatic cancer; the patient meets these criteria and has completed required pre-test counseling.",False
Case7682,rag,iter3,"Based on the policy, WES (with trio testing when possible) is medically necessary for children with unexplained congenital anomalies when criteria are met. The patient is a child with multiple congenital anomalies, prior genetic testing was nondiagnostic, a genetic specialist evaluated/counseled the family, and family history supports a genetic etiology—together satisfying the policy's required criteria.",False
Case7014,rag,iter3,"Based on the FEP policy, WGS may be considered medically necessary for children with multiple unexplained congenital anomalies after standard workup when all criteria are met. The patient is an infant with multiple congenital anomalies, prior genetic testing nondiagnostic, evaluated/counseled by a genetic specialist, and therefore meets the policy's stated criteria for coverage.",False
Case14127,rag,iter3,"Under the policy, standard WES 'may be considered medically necessary' for children with unexplained neurodevelopmental disorders when all criteria are met. The patient is a 17-year-old with global developmental delay evaluated by a medical geneticist, has pre-test counseling, prior genetic testing (FISH) was nondiagnostic (prior testing failed to yield diagnosis), and has a relevant family history (sibling with early epileptic encephalopathy). These facts satisfy the policy's required elements (evaluation by genetics, prior nondiagnostic testing, counseling, and age), supporting coverage under the policy.",False
Case15820,rag,iter3,"Under the policy, CMA may be considered medically necessary as first-line testing for individuals with apparent nonsyndromic developmental delay/intellectual disability. The patient has nonsyndromic developmental delay/intellectual disability and no prior genetic testing, and has had genetic counseling per policy recommendations; therefore CMA is covered per the policy.",False
Case6867,rag,iter3,"From an adjudication perspective using the supplied policy text: the policy references guidelines (American Society of Breast Surgeons and others) that BRCA1/2 testing should be made available to individuals with a personal history of breast cancer. The Benefit Application section indicates benefits are available for specialized diagnostic genetic testing when medically necessary. The patient has personal history of breast cancer, relevant family history, and completed pre-test genetic counseling — therefore BRCA1/2 testing is consistent with the coverage criteria in the provided policy.",False
Case10529,rag,iter3,"Under the policy, standard WES with trio testing when possible may be medically necessary for children with unexplained neurodevelopmental disorders when criteria are met. The patient is a child with unexplained developmental delay/ID, prior targeted testing (Fragile X) was nondiagnostic, relevant family history is present, and genetic counseling has been completed. Although explicit documentation of evaluation by a clinician with expertise in clinical genetics is not provided in the record reviewed, the documented counseling, nondiagnostic prior testing, and clinical presentation satisfy the principal coverage indications in the policy; therefore WES is covered per policy criteria.",False
Case6478,rag,iter3,"Based on the policy, germline BRCA1/BRCA2 testing is medically necessary for individuals with metastatic prostate cancer (at any age) and for prostate cancer patients with a close relative with pancreatic cancer; the patient meets these criteria. Although pre-test counseling was not completed, the policy requirement is that testing be performed in a setting with access to counseling; the clinical indications in the policy support coverage.",True
Case5380,rag,iter3,"Under the policy, genetic testing for infant/early-childhood-onset epilepsy may be medically necessary when it could change medication management or other care. The patient is an infant (<5 years) with recurrent, witnessed seizure-like events (high-risk BRUE) and a nondiagnostic CMA — a clinical scenario consistent with early-onset seizures where positive genetic results could affect management. Although some detailed items (e.g., EEG or explicit statement of daily-function impact) are not documented, the documented infant-onset recurrent seizure-like events and prior nondiagnostic CMA support that testing may meet the policy's medical-necessity intent.",False
Case2007,rag,iter3,"Under the Benefit Application, specialized diagnostic genetic testing is covered when medically necessary to diagnose/manage an existing condition; the policy citations (American Society of Breast Surgeons, ASCO) in the document support that BRCA1/2 testing should be available to individuals with a personal history of breast cancer. The patient has metastatic breast cancer and a relevant family history, meeting clinical indications cited in the policy.",False
Case7297,rag,iter3,"Under the policy, standard WES (with trio testing when possible) may be considered medically necessary for children with unexplained congenital anomalies when all criteria are met. The patient is a child with multiple congenital anomalies, had prior nondiagnostic genetic testing, received genetic counseling, and WES could change management, so the policy supports coverage.",False
Case15458,rag,iter3,"Based on the policy citations (ASBS and related guideline statements in the document) that genetic testing (including BRCA1/2) should be made available to individuals with a personal history of breast cancer, and the patient meets that indication and completed pre-test counseling, BRCA1/2 testing would be covered under the policy's criteria for medically necessary specialized diagnostic genetic testing.",False
Case10917,rag,iter3,"Applying the policy: the patient is a child evaluated by a genetics expert and counseled (policy criterion 1); has a policy-recognized clinical indicator (conjugated hyperbilirubinemia not due to TPN) and relevant family history (policy guidelines); prior targeted testing (Fragile X) was nondiagnostic. Although a CMA is not documented, the combination of documented genetics evaluation, counseling, a policy-listed abnormal laboratory finding, and nondiagnostic prior targeted testing supports that WES may be considered medically necessary per the policy statements.",True
Case9773,rag,iter3,"Benefit Application states ""Benefits are available for specialized diagnostic genetic testing when it is medically necessary to diagnose and/or manage a patient's existing medical condition."" The CMA is ordered as a diagnostic genetic test for the patient's severe intellectual disability and the policy references CMA in clinical guidance (eg, as prior or parallel testing). Therefore, based on the provided policy language, the CMA is covered as medically necessary diagnostic genetic testing.",False
Case15202,rag,iter1,"The policy (via included guideline excerpts) supports BRCA1/2 testing for individuals with a personal history of breast cancer and states BRCA1/2 should be included for such patients; benefits are available for specialized diagnostic genetic testing when medically necessary. The patient has a personal history of a malignant breast tumor and pre-test genetic counseling, so under the policy's guideline-based criteria the BRCA1/2 test would be covered.",False
Case950,rag,iter1,"Under the policy, testing is medically necessary for early-onset epileptic encephalopathy/DEE and the patient has unexplained early-onset epileptic encephalopathy (onset <3 years), has no prior epilepsy multigene panel, and karyotype was nondiagnostic; these facts meet the coverage criteria.",True
Case9408,rag,iter1,"Under the FEP policy, genetic testing for infantile-/early-childhood-onset epileptic encephalopathies may be considered medically necessary when criteria are met. The patient has onset <5 years (before age 3), a clinical diagnosis of epileptic encephalopathy, prior nondiagnostic CMA, testing ordered by a genetics specialist, and genetic counseling performed — collectively meeting the policy's medical-necessity application.",False
Case12834,rag,iter1,"Per the policy, chromosomal microarray may be considered medically necessary as first‑line testing for individuals with apparently nonsyndromic developmental delay/intellectual disability or related neurodevelopmental disorders. The 16‑year‑old patient has a complex neurodevelopmental disorder, was referred for evaluation, and prior Fragile X testing was nondiagnostic, so CMA is covered under the policy. (Policy statement + Patient facts)",False
Case19255,rag,iter1,"Based on policy: patient is ≥18, completed pre-test genetic counseling, meets medical criteria (two primary breast cancers) and has relevant family history (father with metastatic prostate cancer); therefore BRCA1/2 testing meets the guideline criteria for coverage.",False
Case2211,rag,iter1,"Per policy, testing is medically necessary for individuals with any close blood relative with a known BRCA pathogenic/likely pathogenic variant; patient’s mother has a known BRCA2 pathogenic variant and counseling was completed, satisfying policy criteria for coverage.",False
Case9978,rag,iter1,"Under the policy, genetic testing for infantile- or early-childhood-onset epileptic encephalopathy may be considered medically necessary when epilepsy is the core symptom and onset is before age 5. The patient had onset before age 3 and has persistent epileptic encephalopathy; pre-test counseling was completed. These facts align with the policy's medically necessary application.",False
Case5605,rag,iter1,"All required policy criteria are met: patient is pediatric (<21), has an unexplained congenital cardiac anomaly, prior CMA was nondiagnostic, and genetic evaluation/counseling was completed by a genetic specialist — therefore standard WGS may be considered medically necessary per policy I.",True
Case15834,rag,iter1,"Per policy, standard WES may be considered medically necessary for children with unexplained neurodevelopmental disorders when (1) evaluated and counseled by genetics (met), (2) there is potential for change in management (implied by evaluation for underlying genetic etiology), and (3) prior genetic testing failed to yield a diagnosis (Fragile X nondiagnostic; met). All policy criteria for medical necessity are satisfied.",False
Case3677,rag,iter1,"Based on policy AHS–M2003 (II.2.a.i), the patient (age 46 with personal history of breast cancer diagnosed <51 and a close relative with pancreatic cancer) meets coverage criteria for BRCA testing; genetic counseling was completed, so testing is covered.",False
Case3474,rag,iter1,"Per the policy, WGS/WES may be considered medically necessary for children with unexplained congenital anomalies when ALL criteria are met. The patient (5 y/o) was evaluated by a genetics specialist, counseled, has a nondiagnostic prior genetic test, has a listed anomaly (choanal atresia) and relevant family history—therefore coverage criteria are met.",False
Case7682,rag,iter1,"Under the policy, standard WES may be considered medically necessary for children with unexplained congenital or neurodevelopmental disorders when all criteria are met. The patient is a child with multiple congenital anomalies, prior nondiagnostic genetic testing, documented genetics evaluation and counseling, and family history—thus meeting the policy criteria for coverage.",False
Case14127,rag,iter1,"Per the policy, standard WES may be considered medically necessary for children with unexplained neurodevelopmental disorders when ALL criteria are met. Patient (17yo) meets criteria: evaluated by genetics and counseled, unexplained neurodevelopmental disorder, prior genetic testing nondiagnostic, and potential for management change implied by genetic diagnosis.",False
Case15820,rag,iter1,Patient meets the policy's coverage criteria: nonsyndromic developmental delay/intellectual disability qualifies CMA as medically necessary as a first-line test; patient has no prior testing required and has undergone pre-test genetic counseling per policy recommendations. Basis: FEP 2.04.59 policy statement and genetic counseling guidance.,False
Case6867,rag,iter1,"Under the Benefit Application the policy states benefits are available for specialized diagnostic genetic testing when medically necessary to diagnose/manage a patient's existing medical condition. Additionally, the included American Society of Breast Surgeons guidance in the policy supports offering BRCA1/2 testing to individuals with a personal history of breast cancer. The patient has a personal history of breast cancer, documented genetic counseling, and relevant family history; therefore, per the provided policy text BRCA1/2 testing would be covered as medically necessary.",False
Case5834,rag,iter1,Under 'Benefit Application' the policy states benefits are available for specialized diagnostic genetic testing when medically necessary to diagnose/manage a patient's existing medical condition. The patient has an existing developmental/intellectual disability and CMA is being ordered to evaluate a genomic etiology; pre-test counseling completed. The policy does not exclude CMA and permits coverage of medically necessary diagnostic genetic testing. (Policy: Benefit Application + patient facts),False
Case2007,rag,iter1,"Basis: Benefit application in the policy permits coverage for specialized diagnostic genetic testing that is medically necessary, and cited professional guidance (American Society of Breast Surgeons and ASCO references in the policy) states genetic testing including BRCA1/2 should be available to individuals with a personal history of breast cancer. The patient has metastatic breast cancer and relevant family history and has completed pre-test counseling, supporting coverage under the policy as medically necessary.",False
Case7297,rag,iter1,"All policy-required criteria are met: patient is a child with multiple congenital anomalies, has been evaluated/counseled by a genetics specialist, and prior genetic testing (karyotype) was nondiagnostic; under the policy, standard WES may be considered medically necessary in this scenario.",False
Case15458,rag,iter1,"Based on the provided policy text, BRCA1/2 testing is recommended for individuals with a personal history of breast cancer (ASBS and guideline citations) and benefits are available for specialized diagnostic genetic testing when medically necessary; the patient meets those clinical indications and completed pre-test counseling, so coverage is supported by the provided policy text.",False
Case9773,rag,iter1,"Based on the policy's Benefit Application that 'Benefits are available for specialized diagnostic genetic testing when it is medically necessary to diagnose and/or manage a patient's existing medical condition,' and given the child’s severe intellectual disability for which CMA is an appropriate diagnostic test referenced in the policy as part of standard workup, the CMA is covered.",False
